0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of bepridil on metabolic control and insulin secretion in diabetics.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In a double-blind cross-over study bepridil 900 mg followed by 300 mg daily for 11 days was given to 37 insulin (Type I) or non-insulin (Type II)-dependent diabetic patients. It did not modify the metabolic control of the patients as levels of glucose in blood and urine, doses of insulin and oral hypoglycaemic drugs, energy intake, and the number of hypoglycaemic attacks during therapy were unchanged. The serum concentration of C-peptide was not modified in either type of diabetic patient, and serum insulin in the Type I but not in the Type II patients was slightly higher during active drug treatment. No adverse organotoxic or arrhythmogenic effects or changes in possible atherogenic lipid fractions in serum could be demonstrated during bepridil therapy.

          Related collections

          Author and article information

          Journal
          Eur. J. Clin. Pharmacol.
          European journal of clinical pharmacology
          Springer Science and Business Media LLC
          0031-6970
          0031-6970
          1988
          : 34
          : 3
          Affiliations
          [1 ] Medical Department I, Aarhus County Hospital, Denmark.
          Article
          10.1007/bf00540947
          3294020

          Comments

          Comment on this article